Pharmaqube journal
Emerging Therapies in Anemia: From Iron Supplementation to Gene Editing
Abstract
Anemia is induced by a heterogeneity of factors, such as bone marrow malfunction, chronic illnesses, genetic disorders, and nutritional inadequacies. It’s likely to affect more than 1.6 billion people across the world. Although traditional medicines like erythropoiesis-stimulating agents (ESAs) and iron supplements continue to be essential, newer strategies including hepcidin modulators, CRISPR-Cas9 gene editing, and Hypoxia inducible factor (HIF) stabilizers have emerged. In this study range of conventional and innovative therapeutic approaches is examined, together with their mechanisms, clinical developments, and potential future applications in the treatment of customized Anemia.